Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Vilits, T.
Impact of linezolid on hematopoietic engraftment in patients after umbilical cord blood stem cell transplantation
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2015. pp.
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Quehenberger Franz
- Wölfler Albert
- Altmetrics:
- Abstract:
- Abstract Background: Linezolid is approved for the treatment of infections caused by otherwise resistant Gram-positive bacteria, but has been associated with hematologic toxicity in the general population. Thus, there are concerns about its potential myelotoxicity in the setting of allogeneic stem cell transplantation (SCT). Umbilical cord blood SCT is a curative option in patients, who lack a suitable HLA-identical stem cell donor, but it associated with delayed and sometimes incomplete hematological recovery. Methods: We retrospectively analysed the data of 35 patients having undergone umbilical cord blood SCT. The aim of our study was to evaluate the impact of linezolid treatment on neutrophil and platelet engraftment and the occurrence of linezolid resistant bacteria. We used descriptive statistical methods as well as Kaplan Meier curves and Cox regression models to analyse the data. Results: We analysed 35 patients (12 female, 23 male) with underlying malignant haematological diseases treated with umbilical cord blood SCT. 28 patients (80%) were treated with linezolid during the neutropenic phase and 7 patients (20%) were treated alternatively. The median number of days on linezolid therapy after UCB transplantation was 16 days (range 3- 57 days). Neutrophil and platelet engraftment were similar between both groups and did not differ in the time to engraftment as well as in the percentages of patients achieving predefined neutrophil and platelet counts. Linezolid-resistant enterococci were identified in routine cutaneous swabs of 3 out of 28 patients. Conclusion: We found that linezolid had no negative impact on neutrophil and platelet engraftment in patients having undergone UCB-HSCT. Hence it is suggested that linezolid can be administered safely in such patients. However, the occurrence of linezolid resistant gram- positive enterococci may be a matter of concern.